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Background: Viscoelastic tests (VETs) are used widely to monitor hemostasis in 
settings such as cardiac surgery. There has also been renewed interest in cold stored 
platelets (CSP) to manage bleeding in this setting. CSPs are reported to have altered 
hemostatic properties compared to room temperature platelets (RTP), including 
activation of GPIIb/IIIa. We investigated whether the functional differences between 
CSP and RTP affected the performance of the PlateletMapping VET on the TEG 5000 
and 6s analyzer.  
Method: Platelet concentrates were divided equally into CSP (stored at 4°C±2°C) and 
RTP (stored at 22°C±2°C) fractions. Whole blood was treated to induce Platelet 
dysfunction (WBIPD) by incubating with anti-platelet drugs (1.0μM ticagrelor and 
10μM aspirin) or by simulating cardiopulmonary bypass. WBIPD samples were then 
mixed with 20% by volume of CSP or RTP to model platelet transfusion before analysis 
using the PlateletMapping VET.  
Results: Addition of CSP to WBIPD increased the PlateletMapping MAFIBRIN and 
MAADP parameters with the TEG 5000 analyzer (both p<0.0001 compared to addition 
of buffer alone). This effect was not observed with RTP. The differential effect of CSP 
on the MAFIBRIN corrected after pre-incubation with the GPIIb/IIIa antagonist tirofiban 
and was quantitatively less with the PlateletMapping test for the TEG 6s analyzer 
which contains the GPIIb/IIa antagonist abciximab. 
Discussion: The PlateletMapping MAFIBRIN and MAADP test results may be 
misleadingly high with CSP, particularly with the TEG 5000 analyzer, most likely due 
to constitutive activation of GPIIb/IIIa on CSP during storage. TEG PlateletMapping 





Figure 1: TEG PlateletMapping assay percentage (%) inhibition/aggregation is calculated from 
the maximal amplitude (MA) of three TEG assays; MATHROMBIN obtained using the standard 
TEG Kaolin activator, which stimulates thrombin generation in the blood sample. This 
parameter reflects the thrombin-dependent contributions of fibrin plus platelets to clot strength. 
MAFIBRIN obtained using ActivatorF, containing reptilase and FXIII to generate and stabilize 
fibrin clot independently of thrombin. This reflects the fibrin component. MAADP/AA in which 
ActivatorF is combined with the direct platelet activators adenosine di-phosphate (ADP) or 
arachidonic acid (AA). This reflects the contribution of platelet ADP or AA pathways to clot 
strength. The equation shown is used to calculate the ‘% aggregation’ parameter from the 
three MA measurements and represents the contribution of either ADP-mediated or AA-
mediated platelet activation to clot strength. Percentage (%) inhibition = 100 - % aggregation 
 
Figure 2: TEG 5000 PlateletMapping assay maximal amplitude (MA) and calculated 
percentage (%) aggregation of; whole blood with induced thrombocytopathy (WBIPD) and 
addition of 20% v/v buffer alone, WBIPD with a simulated transfusion of 20% v/v, cold stored 
platelets (WBIPD + CSP), and WBIPD with a simulated transfusion of 20% v/v, room 
temperature stored platelets (WBIPD + RTP) (n = 14). A – MATHROMBIN, B – MAFIBRIN, C – MAADP 
and D – Calculated Percentage (%) aggregation. Statistical significance relative to WBIPD * = 
p < 0.05, ** = p< 0.01, *** = p< 0.001, **** = p < 0.0001, ns - non-significance. 
 
Figure 3: TEG MAFIBRIN dose response curve illustrating tirofiban treatment of pooled buffy 
coat CSP (n = 3) with the TEG 5000 analyzer, R2 = 0.93, 95% confidence intervals, 





The use of viscoelastic hemostatic tests (VETs) to guide resuscitation during major 
hemorrhage has increased significantly in recent years and is now recommended by 
the National Institute for Health and Care Excellence (NICE) for cardiac surgery.1 
VETs are also used commonly in other clinical settings such as traumatic or obstetric 
hemorrhage, but are not formally recommended in practice guidelines because 
evidence supporting clinical benefit remains incomplete.2-5  
 
In both of the two most widely adopted VET technologies thromboelastography (TEG; 
Haemonetics, Braintree, MA) and rotational thromboelastometry (ROTEM; TEM 
International, Munich, Germany), clot formation is initiated using specific activators in 
whole blood samples housed in analysis cups with a suspended pin. Clot viscoelastic 
strength is then monitored continuously by detecting the mechanical resistance to 
oscillations applied to either cup (TEG) or pin (ROTEM).  
 
Early versions of these VETs using contact (TEG-Kaolin test) or extrinsic pathway 
(ROTEM-EXTEM test) activators did not distinguish the specific contributions of either 
fibrin or platelets to clot strength. However, subsequent refinements of VETs utilize 
selective coagulation activators and platelet inhibitors to more precisely phenotype 
clot formation.6,7 One example is the TEG PlateletMapping system which enables the 
platelet contribution to clot strength to be inferred from three different measurements 
of the maximum amplitude (MA) of the test traces:8-10 1. MATHROMBIN obtained using 
the standard TEG Kaolin activator, which stimulates thrombin generation in the blood 
sample. This parameter reflects the thrombin-dependent contributions of fibrin plus 
platelets to clot strength. 2. MAFIBRIN obtained using ActivatorF, containing reptilase 
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and FXIII to generate and stabilize fibrin clot independently of thrombin. This reflects 
the fibrin component. 3. MAADP/AA in which ActivatorF is combined with the direct 
platelet activators adenosine di-phosphate (ADP) or arachidonic acid (AA). This 
reflects the contribution of platelet ADP or AA pathways to clot strength.  The main ‘% 
inhibition/aggregation’ parameter from TEG PlateletMapping system is derived from 
the three MA measurements (Figure 1) and represents the contribution of either ADP-
mediated or AA-mediated platelet activation to clot strength. This enables detection of 
the antiplatelet drugs aspirin (inhibits AA-mediated platelet function) and P2Y12-
blockers (inhibit ADP-mediated platelet function), which is critical in settings such as 
cardiac surgery to quantify the impact of anti-platelet drugs on clot strength and to 
guide platelet transfusion. Although initially developed for the TEG 5000 analyzer, the 
TEG PlateletMapping system has now been refined for the cartridge-based TEG 6s 
analyzer. For this analyzer, the ActivatorF reagent used to measure the MAFIBRIN also 
includes the potent GPIIb/IIIa receptor antagonist abciximab.10 This prevents platelet-
fibrin interactions ensuring that the MAFIBRIN only reflects the fibrin component of clot 
strength, thereby enabling a more reliable calculation of platelet ‘percentage 
inhibition/aggregation’.  
 
One important trend in transfusion practice is the emergence of evidence that cold 
stored platelets (CSP) may be a useful alternative to conventional room temperature 
platelets (RTP) is settings such trauma or cardiac surgery.11-15 It is established that 
CSP have altered expression of several surface adhesive receptors including 
GPIIb/IIIa, and also increased basal platelet activation compared to WSP.16-19 Since 
these characteristics are critical for the endpoints of the TEG PlateletMapping test, we 
investigated whether CSP had a different effect on test results compared to RTP when 
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platelets were mixed with coagulopathic blood samples to simulate platelet 
transfusion. 
 
MATERIALS AND METHODS 
Preparation of platelet concentrates 
Apheresis platelets were collected from healthy volunteers using the Trima Accel 
system (TerumoBCT Lakewood, CO) as previously described.17,20-22 Platelets were 
collected as hyper-concentrated double collections, before being split equally into two 
platelet storage bags (Polyolefin PL-2410, Fenwal, Lake Zurich, IL) within two hours. 
Pooled buffy coat platelets were manufactured by NHS Blood and Transplant 
(NHSBT, Bristol UK) as previously described23 in compliance with Blood Safety and 
Quality Regulations, Statutory Instrument 2005 No.50.24  Both preparations were 
suspended in 35% plasma and 65% platelet additive solution (T-PAS, TerumoBCT, 
Lakewood, CO for apheresis and SSP+, MacoPharma, Mouvaux, France for buffy-
coat platelets). Buffy-coat platelet concentrates were separated aseptically 24-36 
hours after donation into two equal volumes into two TOTM bags (MacoPharma, 
Mouvaux, France) for storage at 22ºC ± 2 ºC with continuous agitation (RTP) or at 4ºC 
± 2 ºC without agitation (CSP). 
 
Preparation of Whole blood with induced platelet dysfunction (WBIPD) samples. 
Whole blood (WB) was collected from healthy volunteers by peripheral venipuncture 
into 3.2% trisodium citrate tubes (BD Biosciences, Oxford, UK) in compliance with the 
Declaration of Helsinki. Two platelet dysfunction models were simulated and in this 
analysis are considered together (n = 14) 1.) dual anti-platelet therapy: incubation with 
1.0μM ticagrelor and 10μM acetylsalicylic acid (ASA) for a minimum of 15 minutes (n 
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= 8 samples), and, 2) extracorporeal bypass; WB collected into a 500 mL Capiox 
reservoir (TerumoBCT, Lakewood, CO) containing 1 IU/mL heparin sulfate then 
circulated through an extracorporeal bypass circuit containing a roller pump (Cobe CV 
Model 43600, Sorin Biomedica, Milan, Italy), blood oxygenator (KIDS D100 
Oxygenator, Sorin Biomedica, Milan, Italy) and pressure monitoring catheters (DLP 
catheters, 8 Fr, 12 Fr, Medtronic, Minneapolis, MN). Blood was circulated at a flow 
rate of 0.5 L/min with samples taken for analysis after 6 hours (n = 6 samples). 
 
Mixing experiments and PlateletMapping analysis 
Apheresis CSP or RTP stored between three and seven days were mixed with WBIPD 
samples at a dose of 20% by volume. In control experiments, the same volume of 
PlasmaLyte A pH 7.4 (Baxter, Deerfield, IL) was mixed with the WBIPD samples. The 
sample mixtures were analyzed using the TEG 5000 analyzer according to 
manufacturer’s guidelines.10 In additional experiments to study the effect of additional 
GPIIb/IIIa inhibition, buffy coat CSP were incubated with tirofiban (Correvio Pharma 
Corp. Vancouver, Canada) for at least 15 minutes and analyzed on both TEG 5000 
and 6s platforms. Data were compared by analysis of variance (ANOVA) performed 
using GraphPad Prism version 8.2.1 (GraphPad Software, San Diego, CA). 
 
RESULTS  
Addition of both CSP and RTP increased the TEG 5000 MATHROMBIN in the WBIPD 
samples (both p<0.001 compared to addition of buffer alone, n = 14, figure 2A), 
consistent with reversal of thrombocytopathy. As expected, the TEG 5000 MAFIBRIN 
was not altered by the addition of RTP to WBIPD. However, CSP substantially 
increased the MAFIBRIN (p<0.0001 compared to addition of buffer alone, n = 14, figure 
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2B). There was a small, but non-significant increase in TEG 5000 MAADP with RTP, 
but a significant increase with CSP (p<0.0001 compared to addition of buffer alone, n 
= 14, figure 2C). The net effect of the differences in MAFIBRIN and MAADP between RTP 
and CSP was an apparent reduction in the derived percentage aggregation parameter 
with CSP. However, because of the broad variation in results, this did not reach 
statistical significance (figure 2D). 
 
One explanation for the increased MAFIBRIN with CSP was that increased constitutive 
activation of GPIIb/IIIa could potentially cause the CSP to contribute to clot strength 
even though platelets are not directly activated with the ActivatorF reagent that is used 
to measure the MAFIBRIN. In order to test this, the CSP were incubated with the 
GPIIb/IIIa antagonist tirofiban before mixing with WBIPD and testing using the TEG 
5000 platform. The addition of tirofiban resulted in a dose-dependent decrease in 
MAFIBRIN with CSP, resulting in values similar to those with RTP at tirofiban 
concentrations above 1mM (figure 3). In order to assess whether the inclusion of 
abciximab in the MAFIBRIN channel of the TEG 6s PlateletMapping cartridge reduces 
the CSP MAFIBRIN in the same way as tirofiban, three samples of CSP products were 
analyzed on both TEG 5000 and 6s analyzers simultaneously. The MAFIBRIN was 56.2 
± 3.28 mm (mean± SEM) and 45.2 ± 3.0 mm for TEG 5000 and TEG 6s respectively 
a reduction of 11 mm (19.6%) with TEG 6s.  
 
Together, these observations support that the increased MAFIBRIN with CSP compared 
to RTP was mostly mediated by activated GPIIb/IIIa on CSP and that this particularly 
impacts on the unmodified TEG 5000 PlateletMapping test because a GPIIb/IIIa 




The TEG PlateletMapping assay has proved valuable in the management of patients, 
especially cardiac surgery patients in which there is frequently a complex 
thrombocytopathy that includes the effects of anti-platelet and the mechanical effect of 
cardiopulmonary bypass.2,3,5 The calculation of percentage inhibition/aggregation with 
ADP or AA is essential to resolve the degree of platelet dysfunction. However, this derived 
parameter relies on the MAFIBRIN being an accurate representation of the contribution of 
fibrin to clot strength which can then be subtracted from the MATHROMBIN and MAADP/AA to 
yield the respective platelet contributions. Our results demonstrate that particularly with 
the TEG 5000 PlateletMapping test, this assumption may not be valid in the presence 
of CSP with which there is a dramatic increase in MAFIBRIN compared with equivalent 
quantities of RTP. This differential effect was also observed with the MAADP result, which 
together resulted in a trend towards apparent underestimation of the percentage 
aggregation parameter in the presence of CSP.  
 
We show further that the differential effect of CSP on the TEG 5000 PlateletMapping 
MAFIBRIN can be ameliorated by the addition of the GPIIb/IIIa antagonist tirofiban. This 
observation is consistent with previous observations that cold storage of platelets 
results in constitutive activation of GPIIb/IIIa enabling binding of free fibrinogen in 
plasma, a process responsible for the formation of platelet clumps during cold storage 
in fibrinogen rich medium.19 The bound fibrinogen may also complex for FXIII, 
providing a nucleation site for fibrin polymerisation.17 We propose that addition of 
ActivatorF containing activated FXIII and reptilase for measurement of the 
PlateletMapping MAFIBRIN and MAADP, results in crosslinked fibrin formation, but also 
recruitment of CSP to contribute to clot strength, even though they are not directly 
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activated by the test reagents. This effect is not observed with RTP because GPIIb/IIIa 
activation is minimal at room temperature storage. Consistent with this, the impact of 
CSP on MAFIBRIN is less in the PlateletMapping test developed for the TEG 6s analyzer, 
because of the inclusion of the GPIIb/IIIa antagonist abciximab, although still present. 
The partial reduction in MAFIBRIN in the TEG 6s with CSP may indicate that the dose 
of abciximab in the cartridge is insufficient. These findings indicate that the TEG 6s 
assay has the potential to be optimised further to mitigate against misleading results. In 
the meantime, our data suggest that caution should be exercised in interpreting TEG 
PlateletMapping results in the presence of CSP. Further validation, ideally in the in vivo 
setting is required to ensure patients are not put at risk.  
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